US biotech major Gilead Sciences (Nasdaq: GILD) has reported reduced third-quarter 2016 revenue and profit compared to the same period in 2015.
Total revenue for the quarter was $7.5 billion, a 9.6% drop on the $8.3 billion of the third quarter a year ago, and net income was down by 28% from $4.6 billion to $3.3 billion.
Diluted earnings per share dropped to $2.49 from the $3.06 of the previous year and quarterly profit excluding one-time items was $2.75 per share, below the predictions of analysts which averaged $2.85.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze